Cortexyme, Inc. Human Resources Contracts & Agreements
27 Contracts & Agreements
- Bonus & Incentive Agreements (3 contracts)
- Change of Control Agreements (12)
- Compensation Agreements (1)
- Employment Agreements (3)
- Separation Agreements (6)
- Severance Agreements (2)
- 2019 Equity Incentive Plan and forms of stock award agreements thereunder (Filed With SEC on April 1, 2024)
- Executive Change in Control and Severance Agreement between Quince Therapeutics, Inc. and Charles Ryan, dated as of September 1, 2023 (Filed With SEC on November 14, 2023)
- Transition and Separation Agreement between Quince Therapeutics, Inc. and Karen Smith, dated as of August 4, 2023 (Filed With SEC on November 14, 2023)
- Amended and Restated Outside Director Compensation Policy (Filed With SEC on August 9, 2022)
- Separation Agreement, by and between Cortexyme, Inc. and Leslie Holsinger, dated as of July 31, 2022 (Filed With SEC on August 9, 2022)
- Separation Agreement, by and between Cortexyme, Inc. and Christopher Lowe, dated as of June 10, 2022 (Filed With SEC on August 9, 2022)
- Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Dirk Thye, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)
- Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Karen Smith, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)
- Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Brendan Hannah, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)
- Separation Agreement, by and between Cortexyme, Inc. and Caryn G. McDowell, dated as of May 19, 2022 (Filed With SEC on August 9, 2022)
- Employment Offer Letter, by and between Cortexyme, Inc. and Dirk Thye, dated May 9, 2022 (Filed With SEC on August 9, 2022)
- Employment Offer Letter, by and between Cortexyme, Inc. and Karen Smith, dated May 9, 2022 (Filed With SEC on August 9, 2022)
- Employment Offer Letter, by and between Cortexyme, Inc. and Brendan Hannah, dated May 9, 2022 (Filed With SEC on August 9, 2022)
- Separation Agreement, by and between Cortexyme, Inc. and Michael Detke, dated as of May 2, 2022 (Filed With SEC on August 9, 2022)
- Severance Agreement, dated February 1, 2022, between Stephen Dominy and the Registrant (Filed With SEC on March 1, 2022)
- Severance Agreement, dated February 1, 2022, between Casey Lynch and the Registrant (Filed With SEC on March 1, 2022)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Ted Monohon, dated as of September 21, 2021 (Filed With SEC on October 29, 2021)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Stephen S. Dominy, M.D., dated as of May 19, 2021 (Filed With SEC on August 6, 2021)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Michael Detke, dated as of May 21, 2021 (Filed With SEC on August 6, 2021)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Leslie Holsinger, dated as of May 18, 2021 (Filed With SEC on August 6, 2021)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Christopher Lowe, dated as of May 18, 2021 (Filed With SEC on August 6, 2021)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Caryn McDowell, dated as of May 18, 2021 (Filed With SEC on August 6, 2021)
- Change in Control and Severance Agreement, by and between Cortexyme Inc. and Casey C. Lynch, dated as of May 19, 2021 (Filed With SEC on August 6, 2021)
- Separation Agreement by and between Kristen Gafric and Cortexyme, Inc., dated as of April 27, 2020 (Filed With SEC on August 14, 2020)
- Form of Executive Change in Control and Severance Agreement (Filed With SEC on May 21, 2020)
- 2019 Equity Incentive Plan and forms of stock award agreements thereunder (Filed With SEC on April 29, 2019)
- Executive Incentive Bonus Plan (Filed With SEC on April 12, 2019)
